Biotechnology

Techseriesinsight > Blog > News > Biotechnology

January 2, 2025
PRNewswire
Biotechnology

WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year

WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the 2024 Dow Jones Sustainability Indices...

January 2, 2025
PRNewswire
Biotechnology

Veeda Group Rebrands as ‘Veeda Lifesciences’

Veeda Group has unveiled a new logo and brand identity—Veeda Lifesciences—marking a key milestone in its journey. The new brand name reflects the evolution from a generics-focused Contract Research...

January 2, 2025
PRNewswire
Biotechnology

Fapon Biopharma Introduces FP008 at Biotech Showcase: A Safer and More Effective Immunotherapy for Refractory Cancers

Fapon Biopharma, an innovator in developing therapeutic antibodies and fusion proteins, will present its latest breakthrough immunocytokine, FP008, on Jan 14, 2025, at the Biotech Showcase investor conference, following J.P....

December 24, 2024
Business Wire
Biotechnology

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients...

December 24, 2024
Business Wire
Biotechnology

Anaergia to Supply Organic Waste to Energy Solution to PepsiCo in Colombia

Anaergia Inc. (“Anaergia” or the “Company”) (TSX: ANRG) announced today that its Canadian subsidiary, Anaergia DB Inc., has entered into an integrated technology supply contract with PepsiCo Alimentos Z.F....

December 24, 2024
PRNewswire
Biotechnology

Ractigen Therapeutics Announces First Patient Dosed in Phase I Clinical Trial for RAG-17 in SOD1-ALS

Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing RNA-based innovative therapies, today announced the successful dosing of the first patient in the Phase I clinical trial of RAG-17,...

December 23, 2024
PRNewswire
Biotechnology

Aptamer developed by HKBU for treating rare bone disease ‘X-linked hypophosphatemia’ receives Orphan Drug Designation and Rare Pediatric Disease Designation by U.S. FDA

A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People’s Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People’s Hospital) has discovered...

December 23, 2024
Business Wire
Biotechnology

Ellipses Launches Pioneering Clinical Trial Programme in Middle East

Ellipses Pharma Limited (“Ellipses”), a global drug development company focused on accelerating the development of cancer treatments through an innovative drug development model, announced today it has inaugurated the...

December 20, 2024
PRNewswire
Biotechnology

Rare Disease Consulting: Explore How to Address the Low Prevalence and High Outstanding Therapeutics Needs, and Stay Ahead by Understanding the Gaps in the Rare Diseases Market with DelveInsight

At DelveInsight, we take pride in being a leading provider of pharma competitive intelligence and consulting solutions, specializing in the rare diseases domain. With over 350 epidemiology-based market reports published,...

December 19, 2024
Business Wire
Biotechnology

Roche’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson’s Disease

Prothena Corporation plc (NASDAQ:PRTA), today announced results from the Phase IIb PADOVA study conducted by partner Roche investigating prasinezumab in 586 people with early-stage Parkinson’s disease, treated for a...